Hikma Pharmaceuticals Plc Director/PDMR Shareholding (2385M)

TIDMHIK

RNS Number : 2385M

Hikma Pharmaceuticals Plc

10 January 2023

Hikma Pharmaceuticals PLC

Notification and public disclosure of transactions by persons discharging managerial responsibilities

Said Darwazah

 
 1    Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                      Said Darwazah 
 2    Reason for the notification 
 a)   Position/status           Executive Chairman and CEO 
 b)   Initial notification      Initial notification 
       /Amendment 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
 a)   Name                      Hikma Pharmaceuticals PLC 
 b)   LEI                       549300BNS685UXH4JI75 
 4    Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions have 
       been conducted 
 a)   Description of            Description: Ordinary shares of 10 pence each 
       the financial             ID Code: GB00B0LCW083 
       instrument, type 
       of instrument 
       and identification 
       code 
 b)   Nature of the             Grant of a pledge by Darhold Limited over 500,000 
       transaction               Ordinary Shares of 10 pence each in Hikma Pharmaceuticals 
                                 PLC in favour EFG Bank. Darhold Limited is defined 
                                 as a Person Closely Associated with the Executive 
                                 Chairman and CEO, who is a director and shareholder 
                                 of Darhold. 
 c)   Price(s) and              Price(s): GBP0.00p 
       volume(s)                 Volume(s): 500,000 
 d)   Aggregated information    Aggregated volume: 500,000 
                                 Price: GBP0.00p 
 e)   Date of the transaction   9 January 2023 
 f)   Place of the              Amman 
       transaction 
 

Mazen Darwazah

 
 1    Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                      Mazen Darwazah 
 2    Reason for the notification 
 a)   Position/status           Executive Vice Chairman 
 b)   Initial notification      Initial notification 
       /Amendment 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
 a)   Name                      Hikma Pharmaceuticals PLC 
 b)   LEI                       549300BNS685UXH4JI75 
 4    Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions have 
       been conducted 
 a)   Description of            Description: Ordinary shares of 10 pence each 
       the financial             ID Code: GB00B0LCW083 
       instrument, type 
       of instrument 
       and identification 
       code 
 b)   Nature of the             Grant of a pledge by Darhold Limited over 500,000 
       transaction               Ordinary Shares of 10 pence each in Hikma Pharmaceuticals 
                                 PLC in favour of EFG Bank. Darhold Limited is 
                                 defined as a Person Closely Associated with 
                                 the Executive Vice Chairman, who is a director 
                                 and shareholder of Darhold. 
 c)   Price(s) and              Price(s): GBP0.00p 
       volume(s)                 Volume(s): 500,000 
 d)   Aggregated information    Aggregated volume: 500,000 
                                 Price: GBP0.00p 
 e)   Date of the transaction   9 January 2023 
 f)   Place of the              Amman 
       transaction 
 

Mohammed 'Ali' Al-Husry

 
 1    Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                      Mohammed 'Ali' Al-Husry 
 2    Reason for the notification 
 a)   Position/status           Non-Executive Director 
 b)   Initial notification      Initial notification 
       /Amendment 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
 a)   Name                      Hikma Pharmaceuticals PLC 
 b)   LEI                       549300BNS685UXH4JI75 
 4    Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions have 
       been conducted 
 a)   Description of            Description: Ordinary shares of 10 pence each 
       the financial             ID Code: GB00B0LCW083 
       instrument, type 
       of instrument 
       and identification 
       code 
 b)   Nature of the             Grant of a pledge by Darhold Limited over 500,000 
       transaction               Ordinary Shares of 10 pence each in Hikma Pharmaceuticals 
                                 PLC in favour of EFG Bank. Darhold Limited is 
                                 defined as a Person Closely Associated with 
                                 the Non-Executive Director, who is a director 
                                 and shareholder of Darhold. 
 c)   Price(s) and              Price(s): GBP0.00p 
       volume(s)                 Volume(s): 500,000 
 d)   Aggregated information    Aggregated volume: 500,000 
                                 Price: GBP0.00p 
 e)   Date of the transaction   9 January 2023 
 f)   Place of the              Amman 
       transaction 
 

Helen Middlemist

Deputy Company Secretary, responsible for releasing this announcement

10 January 2023

[phone]

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHGCGDBCBBDGXG

(END) Dow Jones Newswires

January 10, 2023 04:20 ET (09:20 GMT)